LEUKON, INC. CONSULTING AGREEMENTConsulting Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Massachusetts
COMMON STOCKUnderwriting Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.17(b) LICENSE AGREEMENT This Agreement is effective May 2, 1997 ("the Effective Date") by and between LeukoSite, Inc. ("LKS"). a Delaware corporation having an address at 215 First Street, Cambridge, MA 02142, and L & I Partners, L.P., a...License Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations
SERVICE AGREEMENTService Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations
AGREEMENT OF LIMITED PARTNERSHIP OF L & I PARTNERS, L.P.Limited Partnership Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Delaware
1 CONFIDENTIAL TREATMENT EXHIBIT 10.3 LICENSE AGREEMENT Effective as of January 2, 1995 ("Effective Date"), THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of California...License Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • California
C) OA's combinatorial chemistry techniques are still experimental, therefore preparation of the library compounds identified in Appendix B may require a substantial amount to research and development work on the part of OA. Accordingly, OA cannot...Confidentiality Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations
RESEARCH AGREEMENTResearch Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • England
1 CONFIDENTIAL TREATMENT EXHIBIT 10.5 LICENSE AGREEMENT This Agreement is effective March 15, 1995 ("EFFECTIVE DATE") by and between Lynxvale Ltd., having an address at the Old Schools, Cambridge CB2, ITS, England ("LYNXVALE"). and LeukoSite, Inc., a...License Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • England
1 CONFIDENTIAL TREATMENT EXHIBIT 10.8(a) LICENCE AGREEMENT (DOCUMENT IDENTIFICATION CODE: LEUKOSITE/IC/NHLI/0012/LICENCE) THIS AGREEMENT (hereinafter called the "LICENCE AGREEMENT") is made effective the Thirty First day of January, 1996 (hereinafter...Licence Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations
1.2 "IMPROVEMENT INVENTION(S)" shall mean any inventions or discoveries which names Dr. Timothy Springer as an inventor or co-inventor for which a patent application owned by CBR is filed within three years from the date of this Agreement and which...License Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Massachusetts
1 CONFIDENTIAL TREATMENT EXHIBIT 10.9 RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • New York
Critical Information" means that information and material listed in the Material Release Agreement of even date hereof between The Wellcome Foundation Ltd. and Leukosite, Inc. 2 -2-Material Release Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations
WITNESSETH:Research, Development and Marketing Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Massachusetts
MORRELL, PEEL & GAMLEN -Solicitors- 1 St Giles Oxford OX1 3JR 2 THIS AGREEMENT dated 6 October 1994 ("the Effective Date") is made between:Agreement for the Construction and Operation of a Therapeutic Antibody Centre • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations
The terms used in this Agreement have the following meaning: 2 -2-Research Collaboration and License Agreement • August 13th, 1997 • Leukosite Inc • Pharmaceutical preparations • Massachusetts
